T1	Participants 50 148	advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials
T2	Participants 255 368	advanced or recurrent endometrial cancer patients participating in Gynecologic Oncology Group chemotherapy trials
T3	Participants 912 925	1203 patients
T4	Participants 1684 1735	patients with advanced/recurrent endometrial cancer
